Spring is an exciting time for Doctor of Pharmacy (PharmD) graduates, with hooding and commencement celebrations across the United States at our 143 academic pharmacy programs (soon to be 141). To that end, I wish all PharmD graduates in the Class of 2025 success in their career plans, goals, and aspirations. For many, this will include the pursuit of postgraduate training in residencies or fellowships. These graduates have put countless hours into this process, with the intention of securing a postgraduate position that will create a strong foundation for their career journeys.
Historically, we have discussed 3 predominant post-graduation paths for student pharmacists: direct-to-career, postgraduate training, and graduate studies, with the first 2 being the most common of interest. Those who select the direct-to-career path help to impact the workforce challenges of our profession soon after graduation. All graduates should be ready for this, as our present Accreditation Council for Pharmacy Education Standards explicitly states: "Ensure that graduating students are ‘practice-ready’ and ‘team-ready,’ that is, prepared to directly contribute to patient care working in collaboration with other health care providers."1
The downward trend in US PharmD graduates continues, as does the reduction in those taking the North American Pharmacist Licensure Examination (NAPLEX). Thus, the reduced number of newly licensed pharmacists versus PharmD graduates:2
- In 2018, there were 14,905 PharmD graduates and 14,103 taking the NAPLEX for the first time.
- In 2023, there were 12,639 PharmD graduates and 12,229 taking the NAPLEX for the first time.
- In 2024, there were an estimated 12,000 PharmD graduates and 10,466 taking the NAPLEX for the first time.
The number of PharmD graduates will likely dip below 10,000 in the next 5 years (a reduction of 33% from 2018). To add context, in the next year or 2, the number of physician assistant graduates will surpass 11,000 and likely eclipse PharmD graduates.3,4